---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-259349"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2021-08-27T23:59:59+00:00"
generated_at: "2026-06-29T07:26:01.697684+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Arrowhead Pharmaceuticals announces departure of Chief Commercial Officer James Hassard

## Summary
- James Hassard, former Chief Commercial Officer, left the company effective August 23, 2021.
- No replacement or interim appointment was disclosed in the filing.
- Company thanked Mr. Hassard for his service but provided no reason for departure.

## SEC filing metadata
- accession: 0001193125-21-259349
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2021-08-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000119312521259349/0001193125-21-259349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000119312521259349/d184220d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-259349
- JSON: https://secwatch.observer/filing/0001193125-21-259349.json
- Plain text: https://secwatch.observer/filing/0001193125-21-259349.txt

## Key facts
- Executive change
  James Hassard departed as Chief Commercial Officer at ARROWHEAD PHARMACEUTICALS, INC..
  - Action: left
  - Role: Chief Commercial Officer
  source text: Effective August 23, 2021, James Hassard, the former Chief Commercial Officer of Arrowhead Pharmaceuticals, Inc. (the “Company”) is no longer with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000119312521259349/0001193125-21-259349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.